Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Amgen's Imdylltra receives positive CHMP recommendation for extensive-stage small-cell lung cancer treatment in Europe
T-cell engager, oncology, regulatory, competitive - Read more

Eli Lilly, Insilico Medicine expand AI drug discovery collaboration, $115M upfront, $2.75B total value
Research collaboration, AI/ML, drug discovery, milestone payments, small molecule - Read more

GSK, Shanghai Pharmaceutical partner to reintroduce Engerix B hepatitis vaccine to China
Commercialization partnership, vaccine, infectious disease, hepatitis B - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

AstraZeneca's tozorakimab hits Ph3 endpoints for chronic obstructive pulmonary disease targeting IL-33 pathway
Antibody, respiratory disease, monoclonal antibody, COPD, IL-33 target - Read more

Takeda reports positive Ph3 data for zasocitinib (TYK2 inhibitor) in moderate to severe plaque psoriasis
Small molecule, autoimmune, TYK2 inhibitor, plaque psoriasis - Read more

Novocure reports positive Ph2 results for tumor treating fields device in metastatic pancreatic ductal adenocarcinoma
Medical device, cancer, tumor treating fields, metastatic pancreatic cancer, combination therapy - Read more

MoonLake reports positive 40-week Ph3 data for sonelokimab targeting IL-17A/F in hidradenitis suppurativa
Antibody, autoimmune, nanobody, hidradenitis suppurativa, IL-17 inhibitor - Read more

Incyte reports positive 52-week Ph3 data for povorcitinib JAK1 inhibitor in hidradenitis suppurativa
Small molecule, autoimmune, JAK1 inhibitor, hidradenitis suppurativa - Read more

Priovant Therapeutics details Ph3 VALOR data for brepocitinib targeting TYK2/JAK1 in dermatomyositis ahead of FDA decision
Small molecule, autoimmune, JAK inhibitor, dermatomyositis, TYK2/JAK1 dual inhibition - Read more

Biogen's litifilimab meets Ph2 primary endpoint for cutaneous lupus erythematosus in AMETHYST trial
Antibody, autoimmune, monoclonal antibody, cutaneous lupus erythematosus, BDCA2 target - Read more

Kardigan reports positive Ph2 results for tonlamarsen targeting angiotensinogen in uncontrolled hypertension patients
Antisense oligonucleotide, cardiovascular, hypertension, angiotensinogen target - Read more

Bristol Myers Squibb's Camzyos (mavacamten) shows positive Ph3 results in adolescents with obstructive hypertrophic cardiomyopathy
Small molecule, cardiovascular, cardiac myosin inhibitor, hypertrophic cardiomyopathy, pediatric population - Read more

Merck & Co.'s WINREVAIR (sotatercept-csrk) shows positive Ph2 results for combined post- and precapillary pulmonary hypertension with heart failure
Protein therapy, cardiovascular, pulmonary hypertension, heart failure with preserved ejection fraction, activin signaling pathway - Read more

Affibody reports sustained efficacy for izokibep in hidradenitis suppurativa Ph3 trial extension
Protein therapy, autoimmune, affibody, hidradenitis suppurativa, TNF-alpha inhibitor - Read more

AstraZeneca's ESO-T01 (in vivo CAR-T) achieves complete remission in 3 of 5 multiple myeloma patients in Ph1
Cell therapy, cancer, CAR-T, multiple myeloma, BCMA target, in vivo gene delivery - Read more

Terrestrial Bio raises $50M Series C, developing microarray patch therapeutic delivery platform
Platform technology, microarray patch, drug delivery - Read more

Novartis to acquire Excellergy for up to $2B to gain Xolair successor drug Exl-111
Monoclonal antibody, allergy, strategic, major transaction - Read more

Otsuka to acquire Transcend Therapeutics for $700M upfront to gain PTSD drug TSND-201
Small molecule, neurological, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here